MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 16682682.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Central Nervous System Neoplasms
- Cranial Irradiation
- Lymphoma, Non-Hodgkin
- Radiotherapy, Adjuvant